Literature DB >> 9682002

Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes.

F Bischof1, A Melms.   

Abstract

The ligand for CD40 (CD40L) is a type II transmembrane glycoprotein that belongs to the tumor necrosis factor superfamily. CD40L expression on peripheral CD4+ cells is increased upon activation and delivers signals to B lymphocytes which constitutively express CD40. We show that dexamethasone in vitro inhibits CD40L expression in a dose-dependent manner in concentrations ranging from 0.1 to 1 mg/mL. Semiquantitative analysis of CD40L mRNA by RT-PCR revealed that this effect was due to inhibition of CD40L transcription. The inhibitory effect of dexamethasone on CD40L expression was reversible and not due to affection of cell viability. Lymphocytes which have been exposed to dexamethasone in vitro retained the ability to express CD40L after incubation in medium alone for 48 h. Dexamethasone also inhibited PMA/ionomycin induced IL-2 and IFN-gamma production but not CD25 and CD69 expression. Glucocorticoids may exert their immunosuppressive effect in part by suppression of CD40L. Regulation of CD40L expression is steroid sensitive and may be similar or in part identical with IL-2 and IFN-gamma regulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682002     DOI: 10.1006/cimm.1998.1308

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Corticosteroids, IgE, and atopy.

Authors:  P J Barnes
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  The modulation of B7.2 and B7.1 on B cells by immunosuppressive agents.

Authors:  O Jirapongsananuruk; D Y Leung
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

3.  Disseminated strongyloidiasis complicating glioblastoma therapy: a case report.

Authors:  Dawit Aregawi; David Lopez; Mark Wick; W Michael Scheld; David Schiff
Journal:  J Neurooncol       Date:  2009-03-31       Impact factor: 4.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.